IMCAS Paris 2026 trends report did not feel incremental.
It felt structural.
From the moment the press conference began to the final walkthrough of the device floor, the message was consistent: medical aesthetics is no longer a single-vertical industry focused on wrinkle reduction and injectable refinement. It is evolving into a fully integrated ecosystem intersecting with longevity medicine, metabolic health, adipose biology, mental health optimization, and regenerative signaling science.
On the ground were Jenni Nagle, Barry Eichner, Krystal Briglia, and Vincent Wong, attending lectures, interviewing brand leaders, and engaging in clinical-level conversations that made one thing unmistakably clear:
The aesthetic industry of 2026 is smarter, more biologically focused, and more systemically aware than ever before.
Exosomes — the dominant narrative of 2025 — were still present. But they were no longer the only story. Instead, IMCAS Paris 2026 revealed a pivot toward:
- Peptides delivered via mesotherapy
- Adipose tissue regeneration in response to GLP-1 medications
- Skin longevity protocols grounded in cellular signaling
- Precision energy-based devices
- And perhaps most surprising — Transcranial Magnetic Stimulation (TMS) formally entering aesthetic medicine.
This was not hype. It was alignment.
Laser Technician + Medical Esthetician Reviews L+A
Gwendolyn Howard, CLT and LE
I’m delighted with the platform Lipgloss and Aftershave has established for our industry. Their informative videos and up-to-date articles not only offer educational content but also keep me informed about the latest trends and future of aesthetic services. Furthermore, they provide valuable business insights from professionals in our community, offering honest advice on machine platforms, tools, equipment, social media, and skin care lines. Thank you, Jenni and Barry, for maintaining a fun and authentic approach to our platform.
Medical Aesthetics Trends and Predictions for the Future
IMCAS Paris 2026 Press Conference
Before stepping onto the exhibition floor, IMCAS leadership presented a comprehensive macroeconomic analysis of the global aesthetic medicine market. The tone was confident, data-driven, and candid about competitive pressures.
“Spectacular rejuvenation of patient profiles, explosion of male demand, emergence of post-weight loss services linked to new anti-obesity treatments (Ozempic®, Wegovy®): the global market confirms a profound structural transformation, supported by strong growth and unprecedented social acceptance.
Valued at 18 billion euros in 2025, the global market for aesthetic surgery, medicine, and dermatology could reach 23.4 billion euros by 2030, representing a 30% increase, according to joint analyses by IMCAS, Boston Consulting Group (BCG), and Cetas Healthcare Intelligence.
The market is expected to maintain an average trajectory of +5% per year until 2030, while facing increased competitive pressure, particularly in the botulinum toxin and hyaluronic acid filler segments.
The United States maintains its leading position with approximately 45% of the global market and particularly dominates the botulinum toxin segment (56% of global demand).
Europe is expected to show a stable progression of approximately 4% per year (2025–2030 projection), driven mainly by skin boosters and biostimulators.
Asia-Pacific shows the most sustained growth in the global market, with a projected average annual progression around 7% (2025–2030). China stands out as the main engine of this expansion, with growth close to 10% per year.
Injectables — including botulinum toxins, hyaluronic acid fillers, and biostimulators — currently concentrate more than 50% of the global aesthetic medicine market, representing 9.6 billion euros in 2025. The segment’s dynamic (+5% growth per year planned from 2025 to 2030)
Professional active cosmetics constitute one of the most dynamic segments, with an annual growth of +7%, supported by major beauty groups. Its relative weight in the total market is expected to increase from 18 to 20% by 2030.
Energy-based devices such as radiofrequency (RF) devices, ultrasound-based devices (including HIFU), and light-based devices (IPL) represent 17% of the market, with a more moderate growth at 4% per year expected from 2025 to 2030.”
5 Paths to Expanding Patient Base
The press conference then turned from economics to demographics — arguably the more telling indicator of long-term industry health.
1 YOUNGER PATIENTS, PREVENTION-ORIENTED
“Gen Z and Millennials are accessing aesthetic medicine much earlier than previous generations. According to Arcane Research, the average age of patients in France fell from 48 to 42 between 2018 and 2024.”
This shift reframes aesthetic medicine from reactive correction to preventative optimization.
2 A STRONGLY ACCELERATING MALE DEMAND
“According to ISAPS, between 2018 and 2024, the number of surgical interventions performed on men increased by 95%, while non-invasive aesthetic treatments progressed by 116%.”
The male aesthetic market is no longer a secondary vertical — it is now a primary growth engine.
3 GLP-1: A NEW GROWTH LEVER FOR AESTHETIC MEDICINE
“The rise of GLP-1 type anti-obesity treatments (Ozempic®, Wegovy®, Zepbound®) constitutes one of the major developments of the last two years. In the United States, according to NewBeauty, 40% of patients on GLP-1 are new entrants who have never used aesthetic medicine, and 60% of clinics now offer specific services related to the post-weight loss effects of GLP-1.”
This statistic alone explains why adipose regeneration, structural support, and skin laxity correction dominated IMCAS 2026 conversations.
4 LONGEVITY AND PERSONALIZATION: TOWARDS AN INTEGRATED AND CUSTOM-MADE PATIENT EXPERIENCE
“According to data from Boston Consulting Group, the boundaries between aesthetics, global health, and longevity are blurring: 72% of patients wish to access these services within the same establishment, and 76% expect a personalized care plan, while only 52% of practitioners offer it today.”
This gap — between patient expectation and clinic execution — may be the single greatest opportunity in aesthetic medicine.
5 CONSUMER PATHWAYS INTO MEDICAL AESTHETICS
“Consumer entry pathways into medical aesthetics vary significantly by region, reflecting distinct regulatory environments and cultural norms. In the United States, advanced facials are essentially equal to neuromodulators as the most common first aesthetic treatment, driven by less restrictive marketing regulations and a strong cultural acceptance of injectable, drug-based aesthetic solutions.”
The takeaway?
Skin optimization remains the gateway.
Final Reflection
IMCAS Paris 2026 confirmed that aesthetic medicine is no longer about isolated outcomes.
It is about:
- Longevity frameworks
- Biological signaling
- Adipose regeneration
- Mental health optimization
- Precision wavelengths
- Micron-level thermal coagulation
Medical aesthetics has matured.
And IMCAS remains the place where that maturity becomes visible first.